Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
about
Transcription-based prediction of response to IFNbeta using supervised computational methodsNovel type I interferon IL-28A suppresses hepatitis C viral RNA replication.Low-dose oral interferon alpha as prophylaxis against viral respiratory illness: a double-blind, parallel controlled trial during an influenza pandemic year.Effect of oxymatrine on the replication cycle of hepatitis B virus in vitro.Fighting infection using immunomodulatory agents.Control of hepatitis B virus replication by interferons and Toll-like receptor signaling pathwaysFeline immunodeficiency. ABCD guidelines on prevention and management.Experimentally-derived fibroblast gene signatures identify molecular pathways associated with distinct subsets of systemic sclerosis patients in three independent cohorts.Melanoma: Molecular Pathogenesis and Therapeutic ManagementNatural products and synthetic compounds as immunomodulators.Differential Biological Activities of Swine Interferon-α SubtypesFeline herpesvirus-1: ocular manifestations, diagnosis and treatment options.Antigen-specific versus antigen-nonspecific immunotherapeutic approaches for human melanoma: the need for integration for optimal efficacy?Efficacy of antiviral chemotherapy for retrovirus-infected cats: What does the current literature tell us?Immune Control of PRRS: Lessons to be Learned and Possible Ways Forward.The use of oral recombinant feline interferon omega in two cats with type II diabetes mellitus and concurrent feline chronic gingivostomatitis syndrome.Effect of Low-Dose Human Interferon-alpha on Shipping Fever of Thoroughbred Racehorses.Ingested Type I Interferon-State of the Art as Treatment for Autoimmunity Part 2A panel of synthetic antibodies that selectively recognize and antagonize members of the interferon alpha family.Virus-induced unfolded protein response attenuates antiviral defenses via phosphorylation-dependent degradation of the type I interferon receptorThe Use of Recombinant Feline Interferon Omega Therapy as an Immune-Modulator in Cats Naturally Infected with Feline Immunodeficiency Virus: New Perspectives.Interferon-alpha drives T cell-mediated immunopathology in the intestine.Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B.Efficacy of Antiviral Drugs against Feline Immunodeficiency Virus.CD69 on CD56+ NK cells and response to chemoimmunotherapy in metastatic melanoma.Use of recombinant feline interferon and glucocorticoid in the treatment of feline infectious peritonitis.Treatment of a case of refractory feline chronic gingivostomatitis with feline recombinant interferon omega.Interferon-alpha after autologous stem cell transplantation in pediatric patients with advanced Hodgkin's lymphoma.
P2860
Q24809619-52BD88D6-3D8D-4A58-9222-8C97779D851DQ24815995-67EF359F-6C2C-4BE4-8273-56DAA2F47F3FQ30427052-C78AAADC-0BEA-4CCF-B039-0329860BDE88Q33812210-B2CB6B90-0D8B-42C4-8836-57D4BBC5BE01Q34103603-664EDE56-3F8A-4A66-BFF4-61F0D3740994Q34137297-D3C38FA3-CC27-41F2-A368-13EDCCA40C8EQ34983862-162E6A72-B617-40DA-B559-9059ABF11020Q34995163-95B4C628-6772-4E86-8622-563560604C40Q35137163-5507A727-C39F-44CE-801C-AABB365F097FQ35917221-439D1ECC-B15A-43B7-8C62-28B709B48395Q36382807-B99AAF4E-3349-4F81-A91A-53B567D98DD2Q37868314-AF1CD1D7-64F1-453F-8535-96496873D735Q37952804-9A644ACC-AEB9-4C5C-8993-6AA2B18F2C31Q38612672-EDEEEF36-9A1E-4DB9-89D8-6BC676AE7D26Q38668708-46E77301-6C7A-42B7-8190-A2157B4768D7Q39218474-96B09370-740F-478E-BE17-CE93B3742724Q39368819-0BF02BD0-698A-49D6-8C3C-2E7155DE3CEFQ39948674-E1E6C200-94A2-46D1-8FB1-A77FCB1888BDQ41923577-0574D8F3-D184-474D-9BBD-9112E5219CF7Q42551996-2172F5CC-1416-46DB-BF5A-7726886478B0Q43378634-F2557F2B-AB19-46FE-93A2-88D276157F83Q43690829-5862D9E1-F55E-4CC9-A5EE-C3CB0CB13640Q43695474-03E4F5A5-4564-43D1-858A-6085AB0934B7Q44742776-BF8DD4A5-E612-4F94-B7EE-AD8383A4D3F7Q46921510-5DF223A2-0A9D-4AFD-99C2-ACC3F752C4A8Q47660203-95F4D719-64E0-472F-957E-F82939D7AA8EQ51767499-C62C8DB9-989D-4D28-9463-8B333120018FQ53604757-5FDEDEBC-BBE8-4689-81C5-0FD2D5B0C369
P2860
Immunomodulation and therapeutic effects of the oral use of interferon-alpha: mechanism of action.
description
1999 nî lūn-bûn
@nan
1999 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@ast
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@en
type
label
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@ast
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@en
prefLabel
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@ast
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@en
P356
P1476
Immunomodulation and therapeut ...... on-alpha: mechanism of action.
@en
P2093
Tompkins WA
P304
P356
10.1089/107999099313325
P577
1999-08-01T00:00:00Z